ArticleThe British journal of cardiology2026
Risks of bleeding
Article in The British journal of cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anticoagulation with vitamin K antagonists is recommended for prevention of thromboembolism in patients with mechanical heart valves. However, this treatment carries a notable risk of bleeding. We performed a retrospective analysis of patients with mechanical heart valves who were anticoagulated with warfarin, extracting the number and type of mechanical heart valves and their time in therapeutic range (TTR) for various recommended international normalised ratio (INR) ranges. Following this, we carried out a prospective study, over two separate six-month periods, identifying those with mechanical heart valves who sustained a bleeding or thromboembolic event. We identified 409 patients with mechanical heart valves with an overall TTR of 68%. Over 12 months, we recorded 32 possible bleeding incidents in 22 patients. There was one thromboembolic event during this period, specifically a cerebrovascular event. In conclusion, while our data indicate an elevated risk of bleeding, additional larger studies are needed to better understand bleeding risks across different demographic groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.